Table 2 Unadjusted hazard ratios for death or new heart failure
Unadjusted HR | 95% Confidence Interval | P value | |
|---|---|---|---|
ANTHROPOMETRIC | |||
Age (75 y) | 1.70 | 0.92 – 3.17 | 0.093 |
Male sex | 0.92 | 0.67 – 1.27 | 0.614 |
Body mass index >30 | 1.04 | 0.49 – 2.20 | 0.916 |
RISK FACTORS | |||
Familiar history of CAD | 1.16 | 0.68 – 1.96 | 0.588 |
Smoking habit | 2.22 | 1.23 – 4.00 | 0.008 |
Diabetes | 0.88 | 0.45 – 1.70 | 0.698 |
Hypertension | 1.00 | 0.59 – 1.70 | 0.999 |
Hypercholesterolemia | 1.13 | 0.66 – 1.92 | 0.664 |
# risk factors ≥ 3 | 1.58 | 0.93 – 2.69 | 0.093 |
CLINIC | |||
Previous CAD diagnosis | 8.76 | 1.21 – 63.3 | 0.032 |
Previous myocardial infarction | 2.51 | 1.32 – 4.76 | 0.005 |
NYHA classification ≥ 3 | 5.81 | 2.99 – 11.3 | <0.0001 |
Revascularization in the follow-up | 0.36 | 0.15 – 0.85 | 0.019 |
THERAPY | |||
β-blockers | 1.00 | 0.55 – 1.81 | 0.997 |
Ca++−antagonist | 1.15 | 0.63 – 2.12 | 0.644 |
Nitrates | 0.92 | 0.54 – 1.56 | 0.753 |
Loop diuretics | 5.26 | 2.94 – 9.40 | <0.0001 |
Aldosterone antagonist | 5.69 | 3.29 – 9.86 | <0.0001 |
ACE-inhibitors/AT1-receptors antagonist | 1.45 | 0.71 – 2.96 | 0.310 |
ASA | 0.69 | 0.36 – 1.30 | 0.251 |
Statins | 0.94 | 0.53 – 1.68 | 0.837 |
Anticoagulant | 6.38 | 3.49 – 11.7 | <0.0001 |
ECG | |||
Heart rate (≥75 bpm) | 2.80 | 1.62 – 4.84 | <0.001 |
Non sinusal rhythm | 4.19 | 1.67 – 10.54 | 0.002 |
QRS duration | 2.62 | 1.47 – 4.70 | 0.001 |
QTc interval | 4.34 | 2.53 – 7.46 | <0.0001 |
LV hypertrophy | 1.00 | 0.47 – 2.11 | 0.995 |
LBB block | 1.63 | 1.07 – 2.48 | 0.024 |
RBB block | 1.30 | 0.62 – 2.76 | 0.489 |
ST segment depression | 1.60 | 0.73 – 3.54 | 0.245 |
Negative T waves | 1.76 | 1.03 – 3.00 | 0.039 |
Q waves | 1.55 | 0.92 – 2.62 | 0.102 |
ECHOCARDIOGRAPHY | |||
LV EDV (≥ 105 ml/m2) | 4.66 | 2.34 – 9.29 | <0.0001 |
LV ESV (≥ 75 ml/m2) | 8.95 | 4.55 – 17.60 | <0.0001 |
LV EF (≤ 30%) | 12.34 | 6.80 – 22.38 | <0.0001 |
LV WMSI (≥ 2.32) | 10.94 | 5.53 – 21.62 | <0.0001 |
LV mass (≥ 310 g) | 4.89 | 2.05 – 11.70 | <0.001 |
LV diastolic function (≥ pseudo-normal)† | 7.03 | 4.00 – 12.38 | <0.0001 |
Mitral regurgitation (≥ moderate)‡ | 4.67 | 2.68 – 8.13 | <0.0001 |
Pulmonary hypertension | 4.86 | 2.68 – 8.80 | <0.0001 |
RVIT dilatation | 1.45 | 0.92 – 2.30 | 0.112 |
RV dysfunction | 5.17 | 2.48 – 10.80 | <0.0001 |
CMR | |||
LGE total burden ≥ 45% § | 13.61 | 7.32 – 25.31 | <0.0001 |
LGE total burden ≥ 20% # | 6.62 | 3.86 – 11.38 | <0.0001 |
LGE spatial Extent ≥ 68% § | 9.27 | 4.86 – 17.66 | <0.0001 |
LGE spatial Extent ≥16% # | 4.96 | 2.60 – 9.45 | <0.0001 |
LGE transmurality | 4.82 | 2.81 – 8.31 | <0.0001 |